{
    "clinical_study": {
        "@rank": "60524", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be started at 500 mg/day, then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and 2000 mg/day at week 6.  Dosages will be decreased, if needed, due to side effects."
            }, 
            {
                "arm_group_label": "Citicoline", 
                "arm_group_type": "Active Comparator", 
                "description": "Citicoline will be started at 500 mg/day, then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and 2000 mg/day at week 6.  Dosages will be decreased, if needed, due to side effects."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if citicoline, as an add-on therapy, will help\n      reduce alcohol use in outpatients with alcohol dependence."
        }, 
        "brief_title": "Citicoline for Alcohol Dependence", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcohol Dependence", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "detailed_description": {
            "textblock": "A total of 62 outpatients with alcohol dependence will be enrolled in a 12-week, randomized,\n      placebo-controlled trial.  Participants will be randomized to receive either placebo or\n      citicoline.\n\n      Throughout the study, participants will be asked about their alcohol use and any withdrawal\n      or craving symptoms.  Depressive symptoms will be measured as well.  Cognition and memory\n      will be measured as well with a neurocognitive battery. Blood will be drawn at study start\n      and week 12 to measure liver enzyme levels.\n\n      Appointments will be weekly for the entire study.  Participants will have a physician\n      follow-up at every study appointment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women age 18-75 years old with diagnosis of alcohol dependence\n\n          -  Average alcohol use of at least 28 drinks per week and at least 7 heavy drinking days\n             (defined as 4 or more drinks/day for women, 5 or more drinks/day for men) in the past\n             28 days\n\n          -  No alcohol use within 72 hours of randomization (maximum abstinence 7 days)\n\n          -  CIWA-Ar (withdrawal scale) score less than or equal to 8 at randomization (consistent\n             with minimal or no withdrawal symptoms and medication probably not needed)\n\n        Exclusion Criteria:\n\n          -  Vulnerable populations including individuals with intellectual disability or\n             dementia, prison or jail inmates, pregnant or nursing women, or women of childbearing\n             age who will not use acceptable forms of birth control\n\n          -  History of cardiovascular disease, arrhythmias, hypertension, or use of\n             antihypertensives\n\n          -  High risk for suicide (defined as suicide attempt in past 6 months, or current\n             suicidal ideation with plan and intent)\n\n          -  High risk of violence toward others (defined as assault in past 6 months, or violent\n             thoughts with evidence of plan and intent)\n\n          -  Intensive outpatient treatment for substance abuse (AA, NA meetings or weekly\n             therapy/counseling for substance use for at least 28 days prior to randomization will\n             be allowed)\n\n          -  Dependence (not just abuse) on substances other than alcohol or nicotine\n\n          -  History of delirium tremens or other sever alcohol withdrawal symptoms, history of\n             cirrhosis or AST or ALT >3 times normal, or other unstable medical condition (e.g.\n             uncontrolled diabetes)\n\n          -  History of bipolar disorder or schizophrenia\n\n          -  Current major depressive episode (past episodes and current milder depressive\n             symptoms allowed) or other psychiatric disorder that should be a major focus of\n             treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074735", 
            "org_study_id": "072012-088"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Inactive ingredient matching the active comparator in appearance", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sugar pill"
            }, 
            {
                "arm_group_label": "Citicoline", 
                "description": "Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects.  It is a naturally occurring neurochemical in the human body.", 
                "intervention_name": "Citicoline", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CDP-choline", 
                    "cytidine diphosphate-choline"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cytidine Diphosphate Choline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "alcohol dependence", 
            "alcohol abuse"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "contact": {
                "email": "sherwood.brown@utsouthwestern.edu", 
                "last_name": "Sherwood Brown, M.D., Ph.D.", 
                "phone": "214-645-6950"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "The University of Texas Southwestern Medical CEnter"
            }, 
            "investigator": {
                "last_name": "Sherwood Brown, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Citicoline for Alcohol Dependence", 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "Sherwood Brown, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined as days with 4 or more drinks for women, 5 or more drinks for men per week.", 
            "measure": "Heavy Drinking Days per Week", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074735"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Texas Southwestern Medical Center", 
            "investigator_full_name": "Sherwood Brown", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}